XML 74 R60.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition - Additional Information (Detail)
¥ in Billions
1 Months Ended 12 Months Ended
May 17, 2018
USD ($)
PerformanceObligation
Mar. 31, 2017
USD ($)
Apr. 30, 2013
USD ($)
PerformanceObligation
Apr. 30, 2012
USD ($)
Dec. 31, 2018
USD ($)
PerformanceObligation
Milestone
Dec. 31, 2017
USD ($)
Milestone
Dec. 31, 2016
USD ($)
Milestone
Apr. 30, 2013
JPY (¥)
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Deferred revenue, current         $ 26,825,000      
Deferred revenue, non current         15,184,000      
Total revenue         13,469,000 $ 911,000 $ 86,000  
Remaining performance obligations         $ 0      
Number of milestone event probable of occurrence or achieved | Milestone         0 0 0  
Maruishi Pharmaceutical Co., Ltd. [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Number of performance obligations for revenue recognized | PerformanceObligation         2      
License and Milestone Fees [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Total revenue         $ 13,436,000 $ 530,000    
License and Milestone Fees [Member] | Maruishi Pharmaceutical Co., Ltd. [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Total revenue           530,000    
License [Member] | Maruishi Pharmaceutical Co., Ltd. [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Total revenue   $ 843,000       843,000    
Royalty [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Revenue from contract with customer         0      
VFMCRP Agreement [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Deferred revenue, current         26,825,000      
Deferred revenue, non current         15,184,000      
Receivables         0      
Other assets         0      
Deferred revenue $ 55,444,000              
Number of combined performance obligations for revenue recognized | PerformanceObligation 1              
Remaining performance obligations         $ 42,009,000      
Number of performance obligations for revenue recognized | PerformanceObligation 2              
Upfront payment $ 50,000,000              
Premium from sale of stock $ 5,444,000              
Remaining performance obligation, expected timing of satisfaction, year         2020      
VFMCRP Agreement [Member] | License and Milestone Fees [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Total revenue         $ 13,436,000      
Maruishi and CKDP Agreements [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Receivables         0 0    
Other assets         0 0    
Deferred revenue         $ 0 $ 0    
Maruishi Agreement [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Number of performance obligations for revenue recognized | PerformanceObligation     2   2      
Premium from sale of stock     $ 337,000          
Upfront non-refundable, non-creditable license fee and premium from sale of stock     15,337,000          
Maruishi Agreement [Member] | Clinical Development and Regulatory Milestones [Member] | Maximum [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Remaining potential consideration     10,500,000          
Maruishi Agreement [Member] | One-time Sales Milestone [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Remaining potential consideration | ¥               ¥ 1
Maruishi Agreement [Member] | License [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Estimated selling price     10,200,000          
Upfront payments on obligations     9,637,000          
Maruishi Agreement [Member] | R&D Services [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Estimated selling price     6,200,000          
Upfront payments on obligations     $ 5,700,000          
CKDP Agreement [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Premium from sale of stock       $ 83,000        
CKDP Agreement [Member] | Clinical Development and Regulatory Milestones [Member] | Maximum [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Remaining potential consideration       3,750,000        
CKDP Agreement [Member] | License [Member]                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Revenue from contract with customer       $ 646,000